XML 32 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated statement of cash flows - indirect method - BRL (R$)
R$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities      
Net income from continuing operations R$ 2,517,753 R$ 1,538,211 R$ 818,614
Adjustments to reconcile net income to cash provided by operating activities      
Share of profit (loss) of joint ventures and associates (11,908) (12,181) 17,634
Amortization of contractual assets with customers – exclusivity rights 607,446 504,907 282,521
Amortization of right-of-use assets 305,900 288,419 260,716
Depreciation and amortization 848,894 738,904 660,199
Interest and foreign exchange rate variations 1,349,953 1,625,987 1,133,882
Deferred income and social contribution taxes (335,375) (296,459) (242,246)
Current income and social contribution taxes 1,396,321 637,973 430,280
Gain (loss) on disposal or write-off of property, plant and equipment, intangible assets and other assets (192,744) (322,190) (184,189)
Reversal (loss) allowance for expected credit losses (27,190) (49,989) (3,123)
Provision (reversal) for losses with inventories (14,895) 26,356 (826)
Provision for post-employment benefits (2,893) 1,939 (2,393)
Equity instrument granted 38,909 9,944 9,364
Provision for decarbonization - CBIO 740,298 638,542 161,281
Provisions for tax, civil and labor risks 192,975 61,039 93,328
Other provisions and adjustments (201) 5,448 2,332
Cash flows from operations before changes in working capital 7,413,243 5,396,850 3,437,374
(Increase) decrease in assets      
Trade receivables and reseller financing 259,878 (779,239) (956,779)
Inventories 645,301 (1,004,819) (1,626,670)
Recoverable taxes (1,201,440) (2,056,104) (826,133)
Dividends received from subsidiaries and joint ventures 12,041 146 1,005
Other assets (87,797) (224,379) (19,392)
Increase (decrease) in liabilities      
Trade payables and trade payables – reverse factoring (1,700,496) 1,557,837 2,425,821
Salaries and related charges 30,965 130,586 63,066
Taxes payable (25,027) (9,442) 11,733
Other liabilities 218,523 677,016 (55,099)
Acquisition of CBIO (778,885) (635,130) (176,837)
Payments of contractual assets with customers – exclusivity rights (597,798) (710,908) (420,261)
Payments of contingencies (70,128) (84,939) (24,351)
Income and social contribution taxes paid (268,558) (283,331) (230,036)
Net cash provided by operating activities from continuing operations 3,849,822 1,974,144 1,603,441
Net cash provided by operating activities from discontinued operations 0 30,550 982,519
Net cash provided by operating activities 3,849,822 2,004,694 2,585,960
Cash flows from investing activities      
Financial investments, net of redemptions 73,973 1,567,962 1,863,053
Acquisition of property, plant and equipment (1,012,639) (929,236) (1,028,419)
Acquisition of intangible assets (274,691) (277,600) (237,488)
Receipt of intercompany loan owed by Oxiteno S.A. to Ultrapar International 0 3,980,699 0
Net cash consumed by subsidiaries acquisition (265,479) (5,985) 0
Transactions with discontinued operations 0 987,895 0
Investment purchase and sale transactions and other assets (38,143) 0  
Initial direct costs of right-of-use assets (20,503) (12,120) (14,905)
Receipt from related parties 0 0 2,334
Cash provided by disposal of investments and property, plant and equipment 512,827 2,839,676 322,494
Capital increase in subsidiaries, associates and joint ventures 0 (28,000) (25,700)
Capital decrease in subsidiaries, associates, and joint ventures 3,100 0 1,500
Net cash provided (consumed) by investing activities from continuing operations (1,021,555) 8,123,291 882,869
Net cash consumed by investing activities from discontinued operations 0 (220,190) (158,733)
Net cash provided (consumed) by investing activities (1,021,555) 7,903,101 724,136
Loans, financing and debentures      
Proceeds 2,903,031 1,519,580 1,383,611
Repayments (3,149,525) (5,848,611) (2,426,222)
Interest and derivatives paid (1,267,447) (1,398,229) (733,791)
Payments of lease      
Principal (213,527) (351,011) (304,975)
Interest paid (145,586) (6,868) (15,267)
Dividends paid (400,025) (638,280) (705,753)
Proceeds from financial liabilities of customers 7,812 162,895 0
Payments of financial liabilities of customers (197,891) (173,948) 0
Capital increase made by non-controlling interests and redemption of shares 0 21,682 0
Related parties (31,238) (18,926) (177)
Net cash consumed by financing activities from continuing operations (2,494,396) (6,731,716) (2,802,574)
Net cash consumed by financing activities from discontinued operations 0 (179,025) (552,967)
Net cash consumed by financing activities (2,494,396) (6,910,741) (3,355,541)
Effect of exchange rate changes on cash and cash equivalents in foreign currency - continuing operations (29,952) (24,024) (4,547)
Effect of exchange rate changes on cash and cash equivalents in foreign currency - discontinued operations 0 (19,316) 56,553
Increase in cash and cash equivalents - continuing operations 303,919 3,341,695 6,561
Decrease in cash and cash equivalents - discontinued operations 0 (387,981) 0
Cash and cash equivalents at the beginning of the year - continuing operations 5,621,769 2,280,074 2,661,494
Cash and cash equivalents at the beginning of the year - discontinued operations 0 387,981 0
Cash and cash equivalents at the end of the year - continuing operations 5,925,688 5,621,769 2,280,074
Cash and cash equivalents at the end of the year - discontinued operations 0 0 387,981
Non-cash transactions:      
Contingent consideration – acquisition of subsidiaries 0 89,640 0
Addition on right-of-use assets and leases payable 257,201 482,439 227,977
Movement without cash effect of escrow deposits and provisions for tax, civil and labor risks 0 41,888 0
Addition on contractual assets with customers – exclusivity rights 66,565 63,061 269,725
Capital increase performed by non-controlling interests 0 13,519 0
Reversal fund - private pension 0 3,107 2,656
Transfer between trade receivables and property, plant and equipment 25,646 0 0
Issuance of shares related to the subscription warrants – indemnification – Extrafarma acquisition 411 942 1,819
Acquisition of property, plant and equipment and intangible assets without cash effect R$ 104,177 R$ 0 R$ 0